MXCT logo

MXCT MaxCyte, Inc.

NASDAQ · Biotechnology · Healthcare

$1.25
+0.08 (+6.84%)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-bas…

Market Cap: $129.06Mwww.maxcyte.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
50
5 mentions
—
60d
50
6 mentions
—
90d
50
8 mentions
—
news: 8

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 2Sell 0Strong Sell 0
Avg price target$4+220.0%
Low $4Median $4High $4
Current Consensus

Revenue

$10.15M+198.49%
$3.11M$7.29M$11.48M$15.66M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.39
$-0.41–$-0.37
3 analysts
FY2026
$-0.26
$-0.27–$-0.24
2 analysts
FY2027
$-0.23
$-0.24–$-0.22
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Maher Masoud
Sector
Healthcare
Industry
Biotechnology
Employees
91
Beta
1.48
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
0.70
www.maxcyte.com